A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety comparable to the standard formulation given twice a day, researchers said.

For diabetic patients recently started on long-acting insulin, mealtime pramlintide (Symlin) may boost blood sugar control similar to rapid-acting insulin but with fewer side effects, researchers found.

For obese patients with diabetes, a Teflon-like sleeve placed inside the small intestine just beyond the stomach iimproves glycemic control quickly and markedly.

Weight loss with the investigational incretin analog liraglutide targets fat mass preferentially over muscle, Swedish researchers found.

An investigational insulin-sensitizing drug for type 2 diabetes seemed in a small study to have the efficacy of thiazolidinedione agents with less potential for side effects.

Roche’s investigational type 2 diabetes drug taspoglutide has demonstrated significant improvements in glucose control and weight loss after only eight weeks of treatment with a safety and tolerability profile that supports entry into Phase III.

A study examining the effects of hyperglycemia on type 2 diabetes patients after acute myocardial infarction (AMI), the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) study, found no cardiovascular benefits from tightly controlling postprandial variations in blood glucose. See …

Persons with treated type 2 diabetes are at increased risk for developing depression, while a more modest association was found between persons with depression and the risk of diabetes, according to a new study.

Hemoglobin A1C (A1C) levels are strongly associated with subsequent mortality in both men and women without a previous diabetes diagnosis, according to the results of the largest study to date of A1C levels and subsequent mortality risk, reported in the June issue of Diabetes Care. In those without known diabetes at …

A black box warning has been added to the safety labeling for becaplermin gel (Regranex, Johnson & Johnson) to warn of the increased risk for cancer mortality in patients who use 3 or more tubes of the product, the US Food and Drug Administration (FDA) announced on Friday.